Volume 93, Issue S255
ABS15-0311
Free Access

Intraocular Pharmacokinetics of Povidone-iodine and the Effect of Repeat Injection with low concentration on the Experimental S. epidermidis Endophthalmitis

I. Byon

I. Byon

Ophthalmology, Yangsan Hospital, Pusan National University, Yangsan, South-Korea

Ophthalmology, Pusan National University, Busan, South-Korea

Search for more papers by this author
K. Kim

K. Kim

Ophthalmology, Yangsan Hospital, Pusan National University, Yangsan, South-Korea

Search for more papers by this author
J. Yu

J. Yu

College of Pharmacy, Pusan National University, Busan, South-Korea

Search for more papers by this author
I. Yoon

I. Yoon

College of Pharmacy, Mokpo National University, Mokpo, South-Korea

Search for more papers by this author
J. Lee

J. Lee

Ophthalmology, Pusan National University, Busan, South-Korea

Search for more papers by this author
First published: 23 September 2015

Abstract

Purpose

To investigate the safety and a half-life of intravitreal povidone-iodine (PVI) and the efficacy of single and repeat PVI injection in experimental S. epidermidis endophthalmitis.

Methods

In Phase I study, the pharmacokinetics and the safety of PVI were investigated. Forty New Zealand White rabbits receiving intravitreal 0.1% and 0.3% PVI were divided into Group I and II. The pharmacokinetics of PVI was analyzed using high performance liquid chromatography (HPLC). To confirm the safety of intravitreal PVI, electroretinography (ERG) and histologic examination were conducted at baseline, 6 and 12 hours. In Phase II study, the efficacy of PVI for the treatment of S. epidermidis endophthalmitis was evaluated in 4 groups (n = 10 in each group). After the induction of S. epidermidis endophthalmitis, 0.1% and 0.3% PVI were injected once in Group A and B, and three times every second day in Group C and D respectively. The fellow eyes receiving sham injection were the control. ERG, histologic examination and vitreous culture for S. epidermidis were conducted at day 14.

Results

In Phase I, 0.1% and 0.3% PVI groups did not show notable retinal damage in ERG and histologic findings and half-life in vitro was 3.27 and 3.58 hours, respectively. In Phase II, all Groups showed a significant improvement of endophthalmitis, compared to the controls. However, four eyes in Group A and 3 eyes in Group B demonstrated a bacterial growth in vitreous at day 14, but none in Group C and D. In the histologic findings, retinal damage was detected as lymphocyte infiltration in the inner retinal layers of eyes with bacterial growth.

Conclusions

0.1% and 0.3% PVI can be tolerated in rabbit eyes. Half-life of the PVI was about 3 hours in vitreous. Repeat PVI injection with low concentration is likely to be effective and safe for the treatment of S. epidermidis endophthalmitis.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.